Header Logo

Connection

CHADI CALARGE to Humans

Back to Details
This is a "connection" page, showing publications CHADI CALARGE has written about Humans.
CHADI CALARGE
Connection Strength
0.754
Humans
  1. Iron Deficiency and Internalizing Symptoms Among Adolescents in the National Health and Nutrition Examination Survey. Nutrients. 2024 Oct 26; 16(21).
    View in: PubMed
    Score: 0.027
  2. Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults. J Child Adolesc Psychopharmacol. 2023 09; 33(7):260-268.
    View in: PubMed
    Score: 0.024
  3. Re: "Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)" by Kolitsopoulos et al. J Child Adolesc Psychopharmacol. 2023 09; 33(7):294.
    View in: PubMed
    Score: 0.024
  4. Utilization and Predictors of Adjuvant Metformin for Children and Adolescents on Mixed Receptor Antagonists (Second-Generation Antipsychotics). J Am Acad Child Adolesc Psychiatry. 2023 11; 62(11):1245-1255.
    View in: PubMed
    Score: 0.024
  5. Iron Deficiency in Attention-Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Internalizing and Externalizing Disorders, and Movement Disorders. Child Adolesc Psychiatr Clin N Am. 2023 04; 32(2):451-467.
    View in: PubMed
    Score: 0.024
  6. Iron deficiency and internalizing symptom severity in unmedicated adolescents: a pilot study. Psychol Med. 2023 04; 53(6):2274-2284.
    View in: PubMed
    Score: 0.022
  7. Sexual Functioning in Adolescents With Major Depressive Disorder: A Prospective Study. J Clin Psychiatry. 2021 10 05; 82(6).
    View in: PubMed
    Score: 0.022
  8. Gut microbiome in adolescent depression. J Affect Disord. 2021 09 01; 292:500-507.
    View in: PubMed
    Score: 0.021
  9. Predictors of depressive symptom trajectories in a prospective follow-up of late adolescents. Psychol Med. 2020 10; 50(13):2283-2288.
    View in: PubMed
    Score: 0.019
  10. First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome. BMC Psychiatry. 2019 04 24; 19(1):123.
    View in: PubMed
    Score: 0.018
  11. Gut permeability and depressive symptom severity in unmedicated adolescents. J Affect Disord. 2019 03 01; 246:586-594.
    View in: PubMed
    Score: 0.018
  12. CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders. J Affect Disord. 2018 10 15; 239:247-252.
    View in: PubMed
    Score: 0.017
  13. Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. J Pediatr. 2018 10; 201:245-251.
    View in: PubMed
    Score: 0.017
  14. Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. J Child Adolesc Psychopharmacol. 2018 03; 28(2):145-150.
    View in: PubMed
    Score: 0.016
  15. The Effect of Depression, Generalized Anxiety, and Selective Serotonin Reuptake Inhibitors on Change in Bone Metabolism in Adolescents and Emerging Adults. J Bone Miner Res. 2017 Dec; 32(12):2367-2374.
    View in: PubMed
    Score: 0.016
  16. CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):908-915.
    View in: PubMed
    Score: 0.016
  17. Comorbidity of Migraine, Major Depressive Disorder, and Generalized Anxiety Disorder in Adolescents and Young Adults. Int J Behav Med. 2017 08; 24(4):528-534.
    View in: PubMed
    Score: 0.016
  18. Polyunsaturated fatty acid composition and childhood adversity: Independent correlates of depressive symptom persistence. Psychiatry Res. 2017 10; 256:305-311.
    View in: PubMed
    Score: 0.016
  19. Body Composition in Adolescents During Treatment With Selective Serotonin Reuptake Inhibitors. Pediatrics. 2017 Jul; 140(1).
    View in: PubMed
    Score: 0.016
  20. Bone Mass in Boys with Autism Spectrum Disorder. J Autism Dev Disord. 2017 06; 47(6):1749-1755.
    View in: PubMed
    Score: 0.016
  21. Sexual Functioning in Adolescents With Major Depressive Disorder. J Clin Psychiatry. 2016 07; 77(7):957-62.
    View in: PubMed
    Score: 0.015
  22. Toxoplasmosis Titers and past Suicide Attempts Among Older Adolescents Initiating SSRI Treatment. Arch Suicide Res. 2016 Oct-Dec; 20(4):605-13.
    View in: PubMed
    Score: 0.015
  23. Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. J Child Adolesc Psychopharmacol. 2016 06; 26(5):471-7.
    View in: PubMed
    Score: 0.015
  24. Fat distribution and major depressive disorder in late adolescence. J Clin Psychiatry. 2016 Jan; 77(1):84-9.
    View in: PubMed
    Score: 0.014
  25. Iron homeostasis during risperidone treatment in children and adolescents. J Clin Psychiatry. 2015 Nov; 76(11):1500-5.
    View in: PubMed
    Score: 0.014
  26. Rapid adipose deposition with mood disorders. Ann Clin Psychiatry. 2015 Nov; 27(4):283-8.
    View in: PubMed
    Score: 0.014
  27. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015 Oct 06; 5:e652.
    View in: PubMed
    Score: 0.014
  28. Characterization of trabecular bone plate-rod microarchitecture using multirow detector CT and the tensor scale: Algorithms, validation, and applications to pilot human studies. Med Phys. 2015 Sep; 42(9):5410-25.
    View in: PubMed
    Score: 0.014
  29. Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. J Clin Psychiatry. 2015 May; 76(5):607-13.
    View in: PubMed
    Score: 0.014
  30. The effect of psychostimulants on skeletal health in boys co-treated with risperidone. J Pediatr. 2015 Jun; 166(6):1449-54.e1.
    View in: PubMed
    Score: 0.014
  31. Major depressive disorder and bone mass in adolescents and young adults. J Bone Miner Res. 2014 Oct; 29(10):2230-7.
    View in: PubMed
    Score: 0.013
  32. Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2014 Apr; 24(3):120-9.
    View in: PubMed
    Score: 0.013
  33. Iron deficiency in pediatric patients in long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2013 Mar; 23(2):101-9.
    View in: PubMed
    Score: 0.012
  34. Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr. 2012 Dec; 161(6):1010-5.
    View in: PubMed
    Score: 0.011
  35. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011 Dec; 72(12):1685-90.
    View in: PubMed
    Score: 0.011
  36. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol. 2011 Apr; 21(2):163-9.
    View in: PubMed
    Score: 0.010
  37. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010 Dec; 20(6):495-502.
    View in: PubMed
    Score: 0.010
  38. Iron status in toddlerhood predicts sensitivity to psychostimulants in children. J Atten Disord. 2012 May; 16(4):295-303.
    View in: PubMed
    Score: 0.010
  39. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010 Mar; 71(3):338-47.
    View in: PubMed
    Score: 0.010
  40. Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009 Dec; 19(6):320-7.
    View in: PubMed
    Score: 0.009
  41. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May; 19(5):373-82.
    View in: PubMed
    Score: 0.009
  42. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009 Apr; 19(2):101-9.
    View in: PubMed
    Score: 0.009
  43. Fluoxetine for depression relapse prevention. J Am Acad Child Adolesc Psychiatry. 2005 Oct; 44(10):966-7; author reply 967-8.
    View in: PubMed
    Score: 0.007
  44. Electroconvulsive therapy in myasthenia gravis. Ann Clin Psychiatry. 2004 Oct-Dec; 16(4):225-7.
    View in: PubMed
    Score: 0.007
  45. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
    View in: PubMed
    Score: 0.007
  46. The Effectiveness of Metformin in Managing Second Generation Antipsychotic-Induced Weight Gain in Children and Adolescents. J Clin Psychiatry. 2023 Dec 20; 85(1).
    View in: PubMed
    Score: 0.006
  47. The comparative effects of sevoflurane and methohexital for electroconvulsive therapy. J ECT. 2003 Dec; 19(4):221-5.
    View in: PubMed
    Score: 0.006
  48. Visualizing how one brain understands another: a PET study of theory of mind. Am J Psychiatry. 2003 Nov; 160(11):1954-64.
    View in: PubMed
    Score: 0.006
  49. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.006
  50. Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
    View in: PubMed
    Score: 0.006
  51. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.006
  52. Machine Learning-Based Aggression Detection in Children with ADHD Using Sensor-Based Physical Activity Monitoring. Sensors (Basel). 2023 May 21; 23(10).
    View in: PubMed
    Score: 0.006
  53. Inflammatory Markers Profile in Older Adolescents During Treatment with Selective Serotonin Reuptake Inhibitors. J Child Adolesc Psychopharmacol. 2021 08; 31(6):439-444.
    View in: PubMed
    Score: 0.005
  54. One-Day Acceptance and Commitment Therapy Compared to Support for Depressed Migraine Patients: a Randomized Clinical Trial. Neurotherapeutics. 2020 04; 17(2):743-753.
    View in: PubMed
    Score: 0.005
  55. Experiential Avoidance Predicts Persistence of Major Depressive Disorder and Generalized Anxiety Disorder in Late Adolescence. J Clin Psychiatry. 2019 10 22; 80(6).
    View in: PubMed
    Score: 0.005
  56. Pathways linking obesity to neuropsychiatric disorders. Nutrition. 2019 10; 66:16-21.
    View in: PubMed
    Score: 0.005
  57. Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapy. Neonatology. 2014; 105(2):149-54.
    View in: PubMed
    Score: 0.003
  58. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013 May; 23(4):282-9.
    View in: PubMed
    Score: 0.003
  59. An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder. Ann Clin Psychiatry. 2011 Nov; 23(4):270-6.
    View in: PubMed
    Score: 0.003
  60. Theory of mind and schizophrenia: a positron emission tomography study of medication-free patients. Schizophr Bull. 2008 Jul; 34(4):708-19.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.